|
42 Companies |
|
55 Products |
|
55 Products |
|
62 Mechanisms of Action |
|
3 Trials |
|
315 News |
|
| «1234567» |
- Trial completion: Evaluation of Sun Protection Education for Kidney Transplant Recipients (clinicaltrials.gov) - Aug 1, 2014
P=N/A, N=153, Completed, Sponsor: Northwestern University
Recruiting --> Completed
- Trial primary completion date, Biopsy: Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma (clinicaltrials.gov) - Jul 30, 2014
P1, N=100, Active, not recruiting, Sponsor: University of Utah
Recruiting --> Completed Trial primary completion date: Jun 2014 --> Jul 2015
- || veliparib (ABT-888) / AbbVie
Trial primary completion date, Combination therapy, Metastases: A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma (clinicaltrials.gov) - Jul 30, 2014
P2, N=346, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Jun 2014 --> Jul 2015 Trial primary completion date: Jun 2014 --> Oct 2014
- | New P2 trial: Evaluation of Technetium Tc 99m Tilmanocept (Lymphoseek®) Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT and SPECT/CT Imaging (clinicaltrials.gov) - Jul 28, 2014
P2, N=12, Not yet recruiting, Sponsor: Navidea Biopharmaceuticals
- Trial termination, Trial primary completion date: Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=150, Terminated, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Jun 2014 --> Oct 2014 Suspended --> Terminated | Trial primary completion date: Dec 2014 --> Sep 2012; Study due for continuing review
- Trial termination: Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer (clinicaltrials.gov) - Jul 2, 2014
P1, N=35, Terminated, Sponsor: Yale University
Suspended --> Terminated | Trial primary completion date: Dec 2014 --> Sep 2012; Study due for continuing review Active, not recruiting --> Terminated
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial termination, Tumor cell, Metastases: Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells (clinicaltrials.gov) - Jul 1, 2014
P2, N=5, Terminated, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Terminated Completed --> Terminated; Due to slow accrual, the investigator decided to close the study.
- Clinical: Helping Children be Safe Outdoors With Sun Protection (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=2000, Enrolling by invitation, Sponsor: Northwestern University
- || Trial primary completion date: Post-Approval Study of MelaFind (clinicaltrials.gov) - Jun 24, 2014
P=N/A, N=720, Recruiting, Sponsor: MELA Sciences, Inc.
Completed --> Terminated; Due to slow accrual, the investigator decided to close the study. Trial primary completion date: Feb 2014 --> Dec 2014
- || vatalanib (PTK787) / Novartis, Bayer
Trial primary completion date, Combination therapy, Metastases: Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 19, 2014
P1, N=96, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Feb 2014 --> Dec 2014 Trial primary completion date: Sep 2014 --> Dec 2014
- Clinical: A Prospective Comparison of Suture Removal Time for Simple Surgical Defects of the Head and Neck (clinicaltrials.gov) - Jun 19, 2014
P=N/A, N=116, Completed, Sponsor: Sundsvall Hospital
- Trial primary completion date: Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin (clinicaltrials.gov) - Jun 2, 2014
P2, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2014 --> Dec 2014 Trial primary completion date: Jun 2014 --> Mar 2014
- | Hiltonol (poly-ICLC) / Oncovir
Enrollment closed: Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) (clinicaltrials.gov) - Jun 1, 2014
P2, N=20, Active, not recruiting, Sponsor: Dr. Nina Bhardwaj
Trial primary completion date: Jun 2014 --> Mar 2014 Recruiting --> Active, not recruiting
- Clinical: A Tailored Internet Intervention to Reduce Skin Cancer Risk Behaviors Among Young Adults (clinicaltrials.gov) - May 22, 2014
P=N/A, N=1600, Recruiting, Sponsor: Fox Chase Cancer Center
- sirolimus / Generic mfg.
Trial completion date: TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients (clinicaltrials.gov) - May 20, 2014
P3, N=77, Completed, Sponsor: Hospices Civils de Lyon
Recruiting --> Active, not recruiting Trial completion date: Mar 2014 --> May 2014
- | sirolimus / Generic mfg.
Trial completion: TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients (clinicaltrials.gov) - May 20, 2014
P3, N=77, Completed, Sponsor: Hospices Civils de Lyon
Trial completion date: Mar 2014 --> May 2014 Active, not recruiting --> Completed
- Trial completion date: A Randomized Control Trial of Sun Protection Interventions for Operating Engineers (clinicaltrials.gov) - May 18, 2014
P2/3, N=357, Completed, Sponsor: University of Michigan
Active, not recruiting --> Completed Trial completion date: Aug 2014 --> Dec 2013
- | Enrollment change: A Randomized Control Trial of Sun Protection Interventions for Operating Engineers (clinicaltrials.gov) - May 18, 2014
P2/3, N=357, Completed, Sponsor: University of Michigan
Trial completion date: Aug 2014 --> Dec 2013 N=256 --> 357
- | Trial completion: A Randomized Control Trial of Sun Protection Interventions for Operating Engineers (clinicaltrials.gov) - May 18, 2014
P2/3, N=357, Completed, Sponsor: University of Michigan
N=256 --> 357 Active, not recruiting --> Completed
- IL-12 engineered TIL / National Cancer Institute
Trial primary completion date, Metastases: Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes (clinicaltrials.gov) - May 12, 2014
P1/2, N=34, Suspended, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> Dec 2017
- IL-12 engineered TIL / National Cancer Institute
Trial completion date, Metastases: Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes (clinicaltrials.gov) - May 12, 2014
P1/2, N=34, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2014 --> Dec 2017 Trial completion date: Oct 2014 --> Dec 2017
- Young TIL / National Cancer Institute
Trial termination, Metastases: Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma (clinicaltrials.gov) - May 5, 2014
P1/2, N=3, Terminated, Sponsor: National Cancer Institute (NCI)
Trial completion date: Oct 2014 --> Dec 2017 Recruiting --> Terminated; Closed this protocol due to autoimmune toxicity.
- Young TIL / National Cancer Institute
Enrollment change, Metastases: Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma (clinicaltrials.gov) - May 5, 2014
P1/2, N=3, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Terminated; Closed this protocol due to autoimmune toxicity. N=53 --> 3
- Trial initiation date: Green Tea Extract in Treating Patients With Actinic Keratosis (clinicaltrials.gov) - Apr 16, 2014
P2, N=88, Terminated, Sponsor: University of California, Irvine
N=53 --> 3 Initiation date: Mar 2000 --> Aug 1999
- Enrollment change: Green Tea Extract in Treating Patients With Actinic Keratosis (clinicaltrials.gov) - Apr 16, 2014
P2, N=88, Terminated, Sponsor: University of California, Irvine
Initiation date: Mar 2000 --> Aug 1999 N=60 --> 88
- New P2 trial, Metastases: Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma (clinicaltrials.gov) - Apr 9, 2014
P2, N=35, Recruiting, Sponsor: National Cancer Institute (NCI)
- Trial completion: The Skin Savvy Study: A Behavioral Skin Cancer Prevention Intervention (clinicaltrials.gov) - Apr 8, 2014
P1, N=200, Completed, Sponsor: Fox Chase Cancer Center
N=60 --> 88 Active, not recruiting --> Completed
- Enrollment change: Optical Frequency Domain Imaging for Non-melanoma Skin Cancers (clinicaltrials.gov) - Apr 2, 2014
P=N/A, N=90, Recruiting, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed N=10 --> 90
- New P1 trial: Safety Study of a Fluorescent Marker to Visualize Cancer Cells (clinicaltrials.gov) - Mar 25, 2014
P1, N=30, Recruiting, Sponsor: Blaze Bioscience Australia Pty Ltd
- Enrollment open: Safety Study of a Fluorescent Marker to Visualize Cancer Cells (clinicaltrials.gov) - Mar 24, 2014
P1, N=30, Recruiting, Sponsor: Blaze Bioscience Australia Pty Ltd
N=10 --> 90 Not yet recruiting --> Recruiting
- Trial termination: Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma (clinicaltrials.gov) - Mar 19, 2014
P=N/A, N=100, Terminated, Sponsor: New Mexico Cancer Care Alliance
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Sufficient samples collected when 73% of target enrollment was reached.
- linsitinib (ASP7487) / Sling Therap
Trial termination, Metastases: Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN) (clinicaltrials.gov) - Mar 5, 2014
P1/2, N=67, Terminated, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Terminated; Sufficient samples collected when 73% of target enrollment was reached. Suspended --> Terminated; Drug manufacturer, Astellas Pharma, informed us that safety and efficacy of Erlotinib and OSI-906 in other oncology studies was determined to be unfavorable.
- New P2 trial: Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer (clinicaltrials.gov) - Mar 5, 2014
P2, N=10, Terminated, Sponsor: Barretos Cancer Hospital
- Enrollment open, Cytology: Nanocytology Test to Evaluate Skin Cancer in High Risk Patients (clinicaltrials.gov) - Feb 23, 2014
P=N/A, N=30, Recruiting, Sponsor: Northwestern University
Suspended --> Terminated; Drug manufacturer, Astellas Pharma, informed us that safety and efficacy of Erlotinib and OSI-906 in other oncology studies was determined to be unfavorable. Not yet recruiting --> Recruiting
- talabostat (BXCL701) / BioXcel
Trial completion, Metastases: Study of Talabostat in Advanced Melanoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Point Therapeutics
Not yet recruiting --> Recruiting No longer recruiting --> Completed
- |||| sirolimus / Generic mfg.
Trial completion: Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients (clinicaltrials.gov) - Feb 22, 2014
P4, N=86, Completed, Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides (clinicaltrials.gov) - Feb 22, 2014
P1, N=43, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Inlyta (axitinib) / Pfizer
Trial completion, Metastases: Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=32, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- talabostat (BXCL701) / BioXcel
Trial completion, Metastases: Study of Talabostat and Cisplatin in Advanced Melanoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=0, Completed, Sponsor: Point Therapeutics
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Genasense (oblimersen) / Genta
Trial completion: Oblimersen in Treating Patients With Merkel Cell Carcinoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=37, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed No longer recruiting --> Completed
- |||| Allovectin-7 (velimogene aliplasmid) / AnGes MG, Fresh Tracks Therap
Trial completion, Metastases: Phase II Trial of Allovectin-7 (clinicaltrials.gov) - Feb 22, 2014
P2, N=133, Completed, Sponsor: Vical
No longer recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Oncophage (Heat Shock Protein Peptide Complex-96) / Agenus
Trial completion, Metastases: Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma (clinicaltrials.gov) - Feb 22, 2014
P3, N=350, Completed, Sponsor: Agenus, Inc.
Active, not recruiting --> Completed No longer recruiting --> Completed
- | imatinib / Generic mfg.
Trial completion, Metastases: Imatinib Mesylate in Treating Patients With Metastatic Melanoma (clinicaltrials.gov) - Feb 22, 2014
P2, N=22, Completed, Sponsor: M.D. Anderson Cancer Center
No longer recruiting --> Completed Suspended --> Completed
- | celecoxib oral / Generic mfg.
Trial completion: Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome (clinicaltrials.gov) - Feb 19, 2014
P2, N=60, Completed, Sponsor: University of California, San Francisco
Suspended --> Completed Recruiting --> Completed
- | eflornithine topical / Generic mfg.
Trial completion: Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis (clinicaltrials.gov) - Feb 19, 2014
P2b, N=0, Completed, Sponsor: University of Arizona
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Radiation Therapy in Treating Patients With Head and Neck Cancer (clinicaltrials.gov) - Feb 19, 2014
P3, N=460, Completed, Sponsor: Medical Research Council
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion: Photodynamic Therapy in Treating Patients With Basal Cell Skin Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=6, Completed, Sponsor: Roswell Park Cancer Institute
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Trial completion: Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer (clinicaltrials.gov) - Feb 19, 2014
P3, N=1131, Completed, Sponsor: Department of Veterans Affairs
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | semaxanib (SU5416) / Pfizer
Trial completion, Metastases: SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Allovectin-7 (velimogene aliplasmid) / AnGes MG, Fresh Tracks Therap
Trial completion, Metastases: Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: Vical
Active, not recruiting --> Completed No longer recruiting --> Completed